Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Institute of Clinical and Translational Research, Baylor College of Medicine, Houston, Texas; Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas; VA Health Services Research and Development Center for Innovations in Quality, Effectiveness and Safety, Houston, Texas.
Selzman Institute for Kidney Health, Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Am J Kidney Dis. 2021 Nov;78(5):700-708.e1. doi: 10.1053/j.ajkd.2021.02.336. Epub 2021 Apr 24.
RATIONALE & OBJECTIVE: Pulmonary hypertension (PH) is highly prevalent among patients with chronic kidney disease (CKD) not requiring kidney replacement therapy. We studied the associations of PH with mortality, kidney failure, as well as cardiovascular (CV) and non-CV hospitalization among Medicare beneficiaries with a CKD diagnosis.
Retrospective, observational study using a matched cohort design.
SETTING & PARTICIPANTS: Patients with PH (based on 2 claims within 2 years) and patients without PH matched on CKD stage from the Medicare 5% CKD sample (1996-2016).
Presence of pulmonary hypertension.
Mortality, kidney failure, and all-cause, CV, and non-CV hospitalization.
Cox proportional hazards models to assess the association between PH and mortality, adjusting for age, sex, race, and comorbidities. Death was considered as a competing event in Fine-Gray models to assess the association between PH and kidney failure. Negative binomial model was used to evaluate the relationship between PH and all-cause, CV, and non-CV hospitalizations.
30,052 patients with PH and CKD and 150,260 CKD stage-matched patients without diagnosed PH were studied. The median age of the study population was 80.7 years, 57.8% were women, and 10.3% were African Americans. The presence of PH was associated with an increased risk of mortality after 1 (HR, 2.87 [95% CI, 2.79-2.95]), 2-3 (HR, 1.56 [95% CI, 1.51-1.61]), and 4-5 (HR, 1.47 [95% CI, 1.40-1.53]) years of follow-up, and a higher risk of all-cause, CV, and non-CV hospitalization during the same period. PH was also associated with kidney failure in after 1 and 2-3 years but not after 4-5 years of follow-up evaluation. Patients with PH also experienced higher rates of acute kidney injury (AKI), and AKI requiring dialysis support within 30 and 90 days of AKI.
Reliance on billing codes and lack of echocardiogram or right heart catheterization data CONCLUSIONS: Among older Medicare beneficiaries with a CKD diagnosis not requiring kidney replacement therapy, the presence of PH was associated with an increased risk of mortality, kidney failure, and hospitalization. Understanding of the mechanism of these associations, especially the increased risk of kidney failure, requires further study.
肺动脉高压(PH)在未接受肾脏替代治疗的慢性肾脏病(CKD)患者中发病率较高。本研究旨在探讨 PH 与医疗保险受益人群 CKD 患者死亡率、肾衰竭以及心血管(CV)和非 CV 住院之间的相关性。
回顾性、观察性研究,采用匹配队列设计。
医疗保险 5% CKD 样本中(1996-2016 年),在 2 年内通过 2 次理赔诊断为 PH 的患者(基于索赔)与未诊断 PH 的 CKD 分期相匹配的患者。
存在 PH。
死亡率、肾衰竭和全因、CV 和非 CV 住院。
采用 Cox 比例风险模型评估 PH 与死亡率之间的相关性,调整年龄、性别、种族和合并症。在 Fine-Gray 模型中,将死亡视为竞争事件,以评估 PH 与肾衰竭之间的相关性。采用负二项式模型评估 PH 与全因、CV 和非 CV 住院之间的关系。
研究共纳入 30052 例 PH 合并 CKD 患者和 150260 例 CKD 分期相匹配且未诊断 PH 的患者。研究人群的中位年龄为 80.7 岁,57.8%为女性,10.3%为非裔美国人。PH 患者在随访 1 年(HR,2.87 [95%CI,2.79-2.95])、2-3 年(HR,1.56 [95%CI,1.51-1.61])和 4-5 年(HR,1.47 [95%CI,1.40-1.53])后死亡率风险增加,同期全因、CV 和非 CV 住院风险也更高。PH 患者在 1 年和 2-3 年时也与肾衰竭相关,但在 4-5 年随访评估时无相关性。PH 患者还经历了更高的急性肾损伤(AKI)发生率,以及 AKI 后 30 天和 90 天内需要透析支持的 AKI。
依赖于计费代码,缺乏超声心动图或右心导管检查数据。
在未接受肾脏替代治疗的老年医疗保险受益人群中,存在 PH 与死亡率、肾衰竭和住院风险增加相关。需要进一步研究这些相关性的机制,尤其是肾衰竭风险增加的机制。